<DOC>
	<DOCNO>NCT00741273</DOCNO>
	<brief_summary>This study evaluate safety pharmacokinetics two dos orally administer Proellex速 female patient impaired hepatic function healthy volunteer normal hepatic function .</brief_summary>
	<brief_title>Evaluate Safety PK Proellex速 Female Patients With Impaired Hepatic Function Healthy Adults</brief_title>
	<detailed_description>16 subject allocate 2 group . The test group consist 8 female patient moderately impaired hepatic function meet Child-Pugh Class B severity criterion , control group consist 8 healthy female adult volunteer . During Stage I , subject receive single oral dose 25mg Proellex速 ( fast state ) follow Clinical Research Unit ( CRU ) three day . Only subject experience serious adverse event ( SAEs ) adverse event ( AEs ) determine Investigator possibly , probably definitely related treatment participate Stage II . The dose increase single dose 50mg Proellex速 ( fast state ) subject followed Clinical Research Unit ( CRU ) three day . Subjects undergo blood draw several time point .</detailed_description>
	<criteria>Speak , read , understand English Spanish willing able provide write informed consent IRBapproved form prior initiation study procedure ; Female , age 18 48 year Body Mass Index ( BMI ) 18 39 , inclusive , prefer ; however , subject 62 year old , inclusive , may participate ; Subjects moderate hepatic insufficiency must meet Class B level ChildPugh criterion ; Subjects must evidence stable hepatic impairment ; If medication treatment complication liver disease , concomitant chronic illness , subject must take medication stable dose least 10 day prior first dose date continue dose duration study ; Nonsmokers prefer , light moderate smoking allow ( 10 cigarettes/day ) Subject willing remain clinic screen visit two treatment visit ( approximately 3 day treatment visit ) ; Other inclusion criterion may apply Past present history allergic reaction formulation administer study , opinion Investigator , suggest increase potential adverse hypersensitivity ; Pregnant lactating female , woman attempt expect become pregnant time study one month study ; A physical illness within three ( 3 ) month study would interfere study determined Investigator ; An acute illness within five ( 5 ) day study medication administration ; Positive urine drug screen screen visit base laboratory testing ; Other exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>62 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>